Ad
related to: when was rituximab approved
Search results
Results From The WOW.Com Content Network
Rituximab is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B cells. [23] When it binds to this protein it triggers cell death. [18] Rituximab was approved for medical use in 1997. [23] It is on the World Health Organization's List of Essential Medicines. [24]
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
The first FDA-approved therapeutic monoclonal antibody was a murine IgG2a CD3 specific transplant rejection drug, OKT3 (also called muromonab), in 1986. This drug found use in solid organ transplant recipients who became steroid resistant. [39] Hundreds of therapies are undergoing clinical trials. Most are concerned with immunological and ...
Truxima (previously known as CT-P10) is the first biosimilar of the reference monoclonal antibody rituximab that targets CD20 molecule primarily found on the surface of B-cells. Its target indications are rheumatoid arthritis, non-Hodgkin lymphoma and chronic lymphocytic leukemia. [19] [20] It was approved by the EMA in February 2017. [21]
The US Food and Drug Administration (FDA) approved it in March 2017, for the treatment of Merkel-cell carcinoma, [85] an aggressive type of skin cancer. The EMA approved it in September 2017, for the same indication. [87] This is the first FDA-approved treatment for metastatic Merkel-cell carcinoma, a rare, aggressive form of skin cancer. [85]
It was approved by the US Food and Drug Administration (FDA) in March 2017, [11] ... [10] [17] Rituximab is a mouse protein, and is immunogenic in humans, ...
Bendamustine was approved for medical use in the United States in 2008. [3] ... (MCL), with or without prior rituximab-containing chemoimmunotherapy treatment, ...
Idelalisib (trade name Zydelig; codenamed CAL-101, GS-1101; PIK3CD inhibitor): FDA-approved in July 2014 for treatment of three types of blood cancers: treatment of relapsed or refractory chronic lymphocytic leukemia (CLL) in combination with rituximab, treatment of relapsed small lymphocytic lymphoma after at least two prior systemic therapies, and treatment of follicular lymphoma (FL) after ...